Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
AssigneeNammi Therapeutics, Inc.
InventorsDavid Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
Life of this patent
Estimating the term…
Abstract
Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Claims15
A method of treating a subject having or diagnosed with having cancer comprising,
- (i) administering to a human subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier is a liposome, lipid nanoparticle (LNP), or a solid-lipid nanoparticle (SLNP), and wherein the nanocarrier comprises a Toll-Like Receptor (TIR) prodrug, wherein the TLR prodrug comprises TR6 having the following chemical structure:
- and/or TR6(A) having the following chemical structure:
- and wherein the lipid moiety comprises cholesterol hemisuccinate (CHEMS).
Dependencies are inferred from the claim text.